Vericiguat in a real-world heart failure population: a single-centre experience

18 May 2025 (16:00 - 16:45)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Mr Carlos Palacios-Castello

UNIVERSITY HOSPITAL VIRGEN DEL ROCIO, Seville (Spain)

6 More presentations in this session

Presentation thumbnail

A placebo-correcetd effect of the initial eGFR decline following SGLT-2 inhibitor initiation: a systematic review and meta-analysis

Doctor S. Urban (Lubin, PL)

Abstract Slides Video

Presentation thumbnail

Scarred for life - outcomes of ischaemic and non-ischaemic cardiomyopathy after heart failure optimisation

Doctor O. Graham (Craigavon, GB)

Abstract Slides Video

Presentation thumbnail

Estimated multinational budget impact of empagliflozin for heart failure patients with full spectrum of left ventriclular ejection fraction

Doctor E. Kim (Seoul, KR)

Abstract Slides Video

Presentation thumbnail

Quantifying the burden of potentially inappropriate prescribed medicines among people hospitalised with heart failure in Australia: a comparison with ESC recommendations

Associate Professor M. Falster (Sydney, AU)

Abstract Slides Video

Presentation thumbnail

The effect of dapagliflozin on the microvascular endothelial cell function and metabolism in patients with heart failure: a preliminary report

Doctor M. Tarnawska (Gdansk, PL)

Abstract Slides Video

Access the full session

Session thumbnail

Vericiguat, SGLT2 inhibitors and implementation

The Event

Event poster

Heart Failure 2025

18 May 2025 16:00 CET

You may be interested in

Congress Presentation

Use of vericiguat: real-world outcomes and insights from the VERITA registry.

Congress Presentation

Vericiguat

Congress Presentation

Verigicuat: standard therapy for HFrEF?

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources